Credit rating
Company information
About Muna Therapeutics ApS
Muna Therapeutics ApS (CVR number: 41142871) is a company from FREDERIKSBERG. The company recorded a gross profit of -110624.4 kDKK in 2023. The operating profit was -142.5 mDKK, while net earnings were -140.3 mDKK. The profitability of the company measured by Return on Assets (ROA) was -69.8 %, which can be considered poor and Return on Equity (ROE) was -85.3 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 75.5 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. Muna Therapeutics ApS's liquidity measured by quick ratio was 2.7 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.
Financial information
See financialsGross profit (kDKK)
EBIT (kDKK)
Profitability
Solidity
Key figures (kDKK)
See financials2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Volume | ||||
Net sales | ||||
Gross profit | -8 795.85 | -49 692.75 | -98 234.04 | - 110 624.44 |
EBIT | -10 186.77 | -61 469.09 | - 122 450.03 | - 142 517.52 |
Net earnings | -7 382.11 | -61 518.26 | - 127 682.35 | - 140 319.97 |
Shareholders equity total | 16 657.74 | 162 312.99 | 202 044.95 | 126 959.86 |
Balance sheet total (assets) | 24 321.12 | 184 063.68 | 247 517.68 | 168 210.49 |
Net debt | -8 125.35 | - 100 999.50 | - 151 668.83 | -91 006.43 |
Profitability | ||||
EBIT-% | ||||
ROA | -41.8 % | -63.3 % | -61.4 % | -69.8 % |
ROE | -44.3 % | -68.7 % | -70.1 % | -85.3 % |
ROI | -47.0 % | -68.9 % | -68.3 % | -81.2 % |
Economic value added (EVA) | -7 350.03 | -56 798.41 | - 116 967.21 | - 136 543.39 |
Solvency | ||||
Equity ratio | 68.5 % | 88.2 % | 81.6 % | 75.5 % |
Gearing | 30.0 % | 4.6 % | 8.2 % | 9.5 % |
Relative net indebtedness % | ||||
Liquidity | ||||
Quick ratio | 2.1 | 5.3 | 4.0 | 2.7 |
Current ratio | 2.1 | 5.3 | 4.0 | 2.7 |
Cash and cash equivalents | 13 125.34 | 108 532.38 | 168 269.81 | 103 042.87 |
Capital use efficiency | ||||
Trade debtors turnover (days) | ||||
Net working capital % | ||||
Credit risk | ||||
Credit rating | BB | BB | BB | BB |
Variable visualization
Roles
Companies in the same industry
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.